Humacyte (HUMA) Short-term Investments (2021 - 2023)

Humacyte (HUMA) has 3 years of Short-term Investments data on file, last reported at $2.1 million in Q1 2023.

• Short-term Investments for Q1 2023 came in at $2.1 million, down 73.66% year-over-year; the trailing twelve-month figure through Mar 2023 was $2.1 million (down 73.66% YoY), and the FY2022 annual result was $2.1 million, down 73.66% from the prior year.
• Short-term Investments was little changed at $2.1 million in Q1 2023 per HUMA's latest filing, from $2.1 million in the prior quarter.
• Over five years, Short-term Investments peaked at $100.0 million in Q2 2021 and troughed at $2.1 million in Q4 2022.
• A 3-year average of $19.5 million and a median of $8.0 million in 2021 frame the typical range for Short-term Investments.
• On a YoY basis, Short-term Investments climbed as much as 73.66% in 2022 and fell as far as 92.0% in 2022.
• A 3-year view of Short-term Investments shows it stood at $8.0 million in 2021, then plunged by 73.66% to $2.1 million in 2022, then changed by 0.0% to $2.1 million in 2023.
• Business Quant data shows HUMA's Short-term Investments at $2.1 million in Q1 2023, $2.1 million in Q4 2022, and $8.0 million in Q3 2022.